Hypereosinophilic Syndrome Clinical Trial
Official title:
Algorithm for the Early Diagnosis and Treatment of Patients With Eosinophilia
Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is
frequently encountered in internal medicine.
Its causes are varied: atopy, drug allergies, parasitic infections, autoimmune diseases and
solid neoplasias. Over 200 etiologies have been reported, some difficult to diagnose and can
be life-threatening Eosinophilia can be a diagnostic dilemma, as the etiologies are extensive
and varied.
The aim of this study is to assess the feasibility of a diagnostic approach based on a
decision algorithm in a group of patients with eosinophilia.
We assume that a procedure with a hierarchy of additional tests would increase the frequency
of diagnosed cases while decreasing the time to diagnosis.
This procedure defined by an algorithm would even reduce the number of tests necessary to
reach a diagnosis.
Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is
frequently encountered in internal medicine.
Its causes are varied: atopy, drug allergies, parasitic infections, autoimmune diseases and
solid neoplasias. Over 200 etiologies have been reported, some difficult to diagnose and can
be life-threatening
Eosinophilia can be a diagnostic dilemma, as the etiologies are extensive and varied.
The aim of this study is to assess the feasibility of a diagnostic approach based on a
decision algorithm in a group of patients with eosinophilia.
The contribution to the diagnosis of a hierarchical strategy for prescribing additional tests
, based on clinical examination as well as some simple diagnostic tests, has never been
evaluated
We assume that a procedure with a hierarchy of additional tests would increase the frequency
of diagnosed cases while decreasing the time to diagnosis.
This procedure defined by an algorithm would even reduce the number of tests necessary to
reach a diagnosis.
All types of patients are tacked into account: those coming from the university hospital,
referred by general practitioners or by other hospitals.
In addition we address the internal medicine patients ,but also those of Hematology and
Infectious Diseases. A comparison of these various groups would be relevant, since disorders
that may be different.
Once enrolled, the patient is drived by the investigator through the various steps and exams
imposed by the algorithm.
Indeed, during 5 months (Day1 5, 43, 71 , 85 , 99 ,113 and month 5), patient is asked to
comply to the various exams and assessment imposed by the algorithm and that should lead to a
diagnosis
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05334368 -
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
|
Phase 3 | |
Recruiting |
NCT00044304 -
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
|
Phase 2 | |
Completed |
NCT00097370 -
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
|
Phase 3 | |
Completed |
NCT00171912 -
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
|
Phase 2 | |
Terminated |
NCT00171860 -
A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
|
Phase 2 | |
Completed |
NCT00787384 -
Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
|
Phase 2 | |
Recruiting |
NCT03801434 -
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
|
Phase 2 | |
Completed |
NCT00255346 -
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
|
Phase 2 | |
Completed |
NCT03306043 -
A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622
|
Phase 3 | |
Recruiting |
NCT04018118 -
Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
|
||
Completed |
NCT02836496 -
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
|
Phase 3 | |
Completed |
NCT00086658 -
Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
|
Phase 3 | |
Recruiting |
NCT00276926 -
Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
|
Phase 2 | |
Active, not recruiting |
NCT02101138 -
Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome
|
Phase 2 | |
Recruiting |
NCT00091871 -
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
|
||
Completed |
NCT01713504 -
Identification of New Markers in the Hypereosinophilic Syndrome
|
N/A | |
Completed |
NCT00038675 -
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
|
N/A | |
Completed |
NCT00017862 -
Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
|
Phase 2 | |
Terminated |
NCT00230334 -
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
|
Phase 2 | |
Recruiting |
NCT04191304 -
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
|
Phase 3 |